|
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
|
03 August 2015 |
|
AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa
|
27 July 2015 |
|
AstraZeneca completes agreement with Tillotts Pharma for Entocort
|
21 July 2015 |
|
IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer
|
14 July 2015 |
|
AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma
|
09 July 2015 |
|
AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
|
29 May 2015 |
|
AstraZeneca provides update on brodalumab development programme
|
22 May 2015 |
|
AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden
|
18 May 2015 |
|
AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits
|
13 May 2015 |
|
FDA grants Priority Review for potential new indication for Brilinta
|
29 April 2015 |